BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 5, 2026
$8,17
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$6,00rendah 52m
$11,22tinggi 52m
Kapitalisasi Pasar (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
Pendapatan (TTM)
$941M
lencana Anda
Rentang 52M
$6–$11
Peringkat Analis
BUY
Target Harga
$21
P/E
-5.5
ROE
87.8%
Margin Laba Bersih
-40.9%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
BCRX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$8.17
Kapitalisasi Pasar (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
Pendapatan (TTM)
$941M
ROE (TTM)
87.8%
D/E Utang/Ekuitas (MRQ)
-0.9
Rentang 52M
$6–$11
BCRX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang BioCryst Pharmaceuticals, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan435
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
Arus Kas Bebas$345M2016-12-31 → 2025-12-31
Margin bersih-40.9%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | BCRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -5.5rata-rata 5T ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.2rata-rata 5T ≈6.7 | ≈6.7 | 29.2 | Kurang nilai | |
| P/B (MRQ) | -4.6rata-rata 5T ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.3rata-rata 5T ≈-281.5 | ≈-281.5 | · | · | |
| Harga / FCF (TTM) | 5.6rata-rata 5T ≈-13.6 | ≈-13.6 | · | · | |
| Harga / Arus Kas (TTM) | 5.5rata-rata 5T ≈-13.9 | ≈-13.9 | · | · | |
| EV / Pendapatan (TTM) | 2.3rata-rata 5T ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.7rata-rata 5T ≈-14.4 | ≈-14.4 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | BCRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -33.3%rata-rata 5T ≈-32.2% | ≈-32.2% | -1041.7% | Tingkat teratas | |
| EBITDA Margin (Margin EBITDA) | 39.1%rata-rata 5T ≈-31.8% | ≈-31.8% | -1041.7% | Tingkat teratas | |
| Margin Sebelum Pajak (TTM) | -40.5%rata-rata 5T ≈-52.6% | ≈-52.6% | -493.4% | Tingkat teratas | |
| Margin Laba Bersih (TTM) | -40.9%rata-rata 5T ≈-53.3% | ≈-53.3% | -990.1% | Tingkat teratas | |
| ROA (TTM) | -75.8%rata-rata 5T ≈-18.2% | ≈-18.2% | -40.3% | Tingkat teratas | |
| ROE (TTM) | 87.8%rata-rata 5T ≈42.1% | ≈42.1% | -55.6% | Lemah | |
| ROIC | -282.4%rata-rata 5T ≈-118.5% | ≈-118.5% | -55.2% | Lemah |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | BCRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | -0.9rata-rata 5T ≈-0.7 | ≈-0.7 | 0.0 | Utang rendah | |
| Rasio Lancar (MRQ) | 2.3rata-rata 5T ≈3.7 | ≈3.7 | 6.7 | Likuiditas rendah | |
| Rasio Cepat (MRQ) | 2.2rata-rata 5T ≈2.5 | ≈2.5 | 4.5 | Likuiditas rendah | |
| Utang Jangka Panjang / Ekuitas (MRQ) | -0.9rata-rata 5T ≈-0.7 | ≈-0.7 | 0.2 | Utang rendah |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | BCRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 94.1%rata-rata 5T ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 47.8%rata-rata 5T ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 117.9% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | BCRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 1.7rata-rata 5T ≈0.8 | ≈0.8 | 0.1 | Tingkat teratas | |
| Inventory Turnover (Perputaran Persediaan) | 2.8rata-rata 5T ≈0.9 | ≈0.9 | · | · | |
| Receivables Turnover (Perputaran Piutang) | 9.4rata-rata 5T ≈7.4 | ≈7.4 | · | · | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$2.0M | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
23.2%
Laporan Berikutnya
Nov 02, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31 Maret 2026 | $-0.09 | $0.05 | -281.8% | |
| 31 Des. 2025 | $0.01 | $0.04 | -74.1% | |
| 30 Sep. 2025 | $0.06 | $0.04 | 67.1% | |
| 30 Juni 2025 | $0.04 | $0.01 | 179.7% | |
| 31 Maret 2025 | $0.00 | $-0.07 | 100.0% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $875M | $451M | $331M | $271M | $157M |
| Margin Operasi % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Laba Bersih | $264M | $-89M | $-227M | $-247M | $-184M |
| EPS Dilusian | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Rasio Lancar | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Rasio Cepat | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $345M | $-53M | $-97M | $-163M | $-145M |
Pemilik institusional (13F) 345 pengaju · $2.8B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
345
Nilai yang dipegang
$2.8B
Posisi baru
55
Posisi yang keluar
34
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 55 (-22 vs Kuartal sebelumnya) | 34 (-5 vs Kuartal sebelumnya) | 137 (+20 vs Kuartal sebelumnya) | 87 (+8 vs Kuartal sebelumnya) | +4.1M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| BlackRock, Inc. | $238.930.360 | 23.893.036 | 8,46% | Saham |
| VANGUARD GROUP INC | $173.732.325 | 22.273.375 | 6,15% | Saham |
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 5,61% | Saham |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 5,38% | Saham |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 5,35% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 4,03% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 3,95% | Saham |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 3,90% | Saham |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 3,65% | Saham |
| JANUS HENDERSON GROUP PLC | $84.853.520 | 8.908.506 | 3,01% | Saham |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 2,94% | Saham |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 2,40% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $62.493.232 | 6.248.046 | 2,21% | Saham |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 1,88% | Saham |
| UBS Group AG | $50.782.800 | 5.078.280 | 1,80% | Saham |
| BANK OF AMERICA CORP /DE/ | $48.012.840 | 4.801.284 | 1,70% | Saham |
| GOLDMAN SACHS GROUP INC | $44.818.738 | 4.481.874 | 1,59% | Saham |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,42% | Saham |
| Nuveen, LLC | $40.072.370 | 4.007.237 | 1,42% | Saham |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,20% | Saham |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,13% | Saham |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,02% | Saham |
| JANE STREET GROUP, LLC | $27.626.830 | 2.762.683 | 0,98% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $27.187.810 | 2.718.781 | 0,96% | Saham |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 0,92% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 0,90% | Saham |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 0,89% | Saham |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 0,89% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 0,83% | Saham |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 0,83% | Saham |
| NORTHERN TRUST CORP | $22.557.310 | 2.255.731 | 0,80% | Saham |
| AQR CAPITAL MANAGEMENT LLC | $22.143.020 | 2.214.302 | 0,78% | Saham |
| MORGAN STANLEY | $19.996.852 | 1.999.684 | 0,71% | Saham |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,67% | Saham |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,66% | Saham |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,66% | Saham |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,65% | Saham |
| STIFEL FINANCIAL CORP | $18.262.340 | 1.826.234 | 0,65% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,62% | Saham |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,62% | Saham |
| JUPITER ASSET MANAGEMENT LTD | $16.428.740 | 1.642.874 | 0,58% | Saham |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,58% | Saham |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,58% | Saham |
| Legal & General Group Plc | $14.555.141 | 1.455.514 | 0,52% | Saham |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,48% | Saham |
| Invesco Ltd. | $12.337.830 | 1.233.783 | 0,44% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,42% | Saham |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,42% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,42% | Saham |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,40% | Saham |
Aktivis & pemilik 5%+ 15 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 pengajuan | 31 Juli 2018 | · | Pengajuan awal | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 April 2018 | · | Pengajuan awal | Investasi pasif | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 pengajuan | 16 Agu 2016 | · | Pengajuan awal | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 pengajuan | 23 Okt. 2012 | · | Pengajuan awal | M&A / penjualan | SEC |
| Julian C. Baker, Felix J. Baker ×4 pengajuan | 13 Okt. 2011 | · | Pengajuan awal | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 pengajuan | 20 Agu 2007 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 7 Des. 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 7 Des. 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 7 Des. 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan | 13 Okt. 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 26 Feb. 2004 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 25 Feb. 2004 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 24 Feb. 2004 | · | Pengajuan awal | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 pengajuan | 31 Okt. 2003 | · | Pengajuan awal | · | SEC |
| William W. Featheringill | 14 Feb. 2002 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 51 orang dalam · 21 pejabat · 30 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 Des. 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 Des. 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 Feb. 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 Maret 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 Des. 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 Maret 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 Mei 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 6 April 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 Maret 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 Des. 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 Nov. 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 Maret 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 Des. 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 Jan. 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 Maret 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 Feb. 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 Maret 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 Juli 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 Juli 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 Juli 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 Mei 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Direktur | 31 Agu 2026 A | 47.821 | 0 | 1 | $-100.285 |
| Jill C. Milne | Direktur | 31 Agu 2026 A | 33.226 | 0 | 0 | $0 |
| Steven Frank | Direktur | 31 Agu 2026 A | 36.747 | 0 | 0 | $0 |
| Jon P Stonehouse | Direktur | 31 Agu 2026 A | 1.340.419 | 0 | 0 | $0 |
| Vincent Milano | Direktur | 31 Agu 2026 A | 109.642 | 0 | 0 | $0 |
| Theresa Heggie | Direktur | 11 Juni 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Direktur | 11 Juni 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Steven K Galson | Direktur | 11 Juni 2026 A | 27.794 | 0 | 0 | $0 |
| Alan G Levin | Direktur | 11 Juni 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Direktur | 12 Juni 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Direktur | 12 Juni 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Direktur | 12 Juni 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Direktur | 13 Juni 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direktur | 28 Feb. 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Direktur | 28 Nov. 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Direktur | 20 Juni 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Direktur | 24 Mei 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | Direktur | 29 Feb. 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Direktur | 2 Mei 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Direktur | 23 Mei 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Direktur | 23 Mei 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Direktur | 12 Mei 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Direktur | 13 Mei 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Direktur | 13 Mei 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Direktur | 16 Mei 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Direktur | 16 Mei 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Direktur | 18 Maret 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Direktur | 17 Mei 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Direktur | 4 Nov. 2003 M | 46.785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21 Mei 2008 A | · | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 41 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,35% | 1.193.733 SH | 1 Okt. 2026 | Harian |
| BBP · ETFis Series Trust I | 1,42% | 155.993 NS | 31 Juli 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0,99% | 510 NS | 31 Juli 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,92% | 1.078.429 NS | 31 Juli 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 248.560 NS | 31 Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,59% | 324.702 NS | 31 Juli 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,36% | 516.595 NS | 31 Juli 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,23% | 73.039 SH | 1 Okt. 2026 | Harian |
| PWS · Pacer Funds Trust | 0,17% | 4.436 NS | 31 Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 19 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,14% | 18.119 SH | 1 Okt. 2026 | Harian |
| ESSC · Strategy Shares | 0,14% | 5.593 NS | 31 Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,13% | 1.651.139 SH | 11 Sep. 2026 | Harian |
| IWO · iShares Trust | 0,13% | 2.178.966 SH | 11 Sep. 2026 | Harian |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 174.467 NS | 31 Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 64.429 NS | 31 Juli 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 46.799 NS | 31 Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 19 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,07% | 111.471 NS | 31 Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 75.067 SH | 11 Sep. 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 207.179 SH | 1 Okt. 2026 | Harian |
| IWM · iShares Trust | 0,06% | 5.937.121 SH | 11 Sep. 2026 | Harian |
| DFAS · Dimensional ETF Trust | 0,05% | 770.732 NS | 31 Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 19 Agu 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 19 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 99.007 NS | 31 Juli 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 19 Agu 2026 | Harian |
| WSML · iShares Trust | 0,01% | 11.812 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 72.998 SH | 11 Sep. 2026 | Harian |
| ITOT · iShares Trust | 0,00% | 336.323 SH | 11 Sep. 2026 | Harian |
| DFUS · Dimensional ETF Trust | 0,00% | 52.194 NS | 31 Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.571 NS | 31 Juli 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 286 NS | 31 Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 19 Agu 2026 | Harian |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 196.622 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 19.676 SH | 19 Agu 2026 | Harian |
| ESGV · VANGUARD WORLD FUND | 0,00% | 51.624 SH | 19 Agu 2026 | Harian |
| ISCB · iShares Trust | · | 10.494 SH | 11 Sep. 2026 | Harian |
| SMLF · iShares Trust | · | 766.086 SH | 11 Sep. 2026 | Harian |
BCRX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 17 analis
BELI
Target median
$17.00
+108,1%
5 29,4%
Beli Kuat
10 58,8%
Beli
2 11,8%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
11 analis · 2026-09-28Target rata-rata $20.64 +152,6%
← Di bawah semua target
Harga saat ini $8.17
Rendah$11.00
Rata-rata$20.64
Tinggi$32.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
RBC Capital Meningkatkan PT BioCryst Pharmaceuticals (BCRX) sebagai Bagian dari Pratinjau Hasil Q1 2026 di Sektor Biotek
Yahoo Finance · 5 bulan lalu
BioCryst (BCRX) Naik 7.10% karena Rumor Akuisisi
Yahoo Finance · 6 bulan, 1 minggu lalu
BioCryst Pharmaceuticals, Inc. (BCRX) Saham yang Bagus untuk Dibeli Sekarang?
Yahoo Finance · 6 bulan, 1 minggu lalu
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 5, 2026